Supporters

José Luis Alloza, MD, PhD.
Director, Alcalá Clinical Pharmacology Project for Drug Research and Development. Dep. de Farmacología-Facultad de Medicina. The Universtiy of Alcalá. Madrid, Spain.

G. Lawrence Atkins, PhD.
Executive Director, Public Policy and Reimbursement. Schering-Plough Corporation. Washington, DC.

Michael N. Cook, PhD, MSc, MSPH.
Director, Epidemiology, Global Safety Surveillance & Epidemiology. Wyeth Research. Collegeville, PA.

Christina Farup, MD, MS.
Vice President, Evidence Based Medicine. Novartis Pharmaceuticals Corporation. East Hanover, NJ.

Joy Frestedt, PhD, RAC, CCTI.
President and CEO, Frestedt Incorporated. St. Louis Park, MN.

R.M.C. Herings, PharmD, MPH, PhD, FISPE.
Director, PHARMO Institute. Associate Professor of Pharmacoepidemiology, Department of Health Policy and Management. Erasmus MC. Rotterdam, The Netherlands.

Mark V. Johnston, PhD.
Professor, Occupational Therapy, College of Health Sciences. University of Wisconsin-Milwaukee. Milwaukee, WI.

Kristijan Kahler Ph.D., R.Ph.
Director, HE&OR, ABGU & NS Evidence Based Medicine. Novartis Pharmaceuticals Corporation. East Hanover, NJ.

Jeff Schein, DrPH, MPH.
Senior Director, Outcomes Research, Internal Medicine. Ortho-McNeil Janssen Scientific Affairs. Raritan, NJ.

Hemal Shah, PharmD.
Executive Director, Health Economics & Outcomes Research. Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT.

J. Michael Sprafka, MPH PhD.
Epidemiology and Pharmacoeconomics. Procter & Gamble. Mason, OH.